MELBOURNE, Australia--(Business Wire)--
Anadis Ltd. (ASX:ANX; OTC:ANDIY) an Australian biopharmaceutical
company specializing in oral immunotherapy using naturally derived
antibodies and other proteins is announcing the clinical protocol for
its Cancer-related Mucositis Program was cleared by the Tel Aviv
Souraski Medical Center's Institutional Review Board (IRB) and by the
Israeli Ministry of Health (MOH). This enables the initiation of the
clinical trial addressing this significant target at the medical
center within a month.
Mucositis is a significant side effect in cancer therapy (between
20% and 100% of patients, depending on the type of cancer and
treatment). It is characterized by intestinal tissue destruction
throughout the GI tract, including painful mouth ulcerations and
severe gastrointestinal symptoms interfering with nutrition and
treatment. There are currently no effective treatments for GI
Mucositis available in the marketplace and treatment for Oral
Mucositis is very expensive and limited to a narrow group of eligible
patients. In the U.S. alone there are more than 10 million patients
undergoing cancer treatments and 1.5 million new cancer cases each
year.
The intended product, primarily for the oncology market, will
leverage a unique formulation of Anadis' immune milk-derived anti LPS
antibodies, growth factors and other bioactives combined and delivered
using Anadis' patented oral delivery technology. Anadis anticipates a
commercial product could reach the market within 2-3 years, due to the
product's excellent safety profile.
Anadis recently announced the receiving a significant grant (see
"Anadis Awarded VISTECH grant for Clinical Trial of Polyclonal
Antibodies for the Treatment of Cancer Related Mucositis" July 1,
2008) to help fund this important program.
Anadis Limited (ASX: ANX; OTC: ANDIY) is a biopharmaceutical
company focused on antigen-primed, dairy-derived health products.
Anadis' proprietary technology enables rapid development of polyclonal
antibody and other proteins-based solutions to a range of important
diseases. The all-natural colostrum-derived platform, its high safety
profile when administered orally and the proprietary methods of
manufacturing, allows for short time-frame from bench to market with
high manufacturing scalability.
Keyword Tags: antibodies, cancer, milk, mucositis, oncology,
polyclonal antibody
Anadis Ltd.
VP, Business Development
Dr. Oren Fuerst, +1 646 536 9289
oren@anadis.com
or
VP, Research and Development
Gran Rawlin, +61 3 9018 4880
grant@anadis.com
or
Investor Relations
Arie Nudel, +61 3 9018 4880
arie.n@anadis.com.au
Copyright Business Wire 2008
